Vascular Biogenics - VBLT Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View VBLT analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued twelve-month price objectives for Vascular Biogenics' shares. Their VBLT share price forecasts range from $5.00 to $5.50. On average, they predict the company's stock price to reach $5.17 in the next year. This suggests a possible upside of 3,799.4% from the stock's current price.
View analysts price targets for VBLT or view top-rated stocks among Wall Street analysts.

Vascular Biogenics' stock was trading at $0.12 at the beginning of 2023. Since then, VBLT shares have increased by 10.4% and is now trading at $0.1325.
View the best growth stocks for 2023 here.

Vascular Biogenics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,240,000 shares, an increase of 699.5% from the February 13th total of 155,100 shares. Based on an average trading volume of 4,340,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.8% of the shares of the company are short sold.
View Vascular Biogenics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 16th 2023.
View our VBLT earnings forecast.

Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company earned $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative trailing twelve-month return on equity of 103.43% and a negative net margin of 4,465.93%. During the same quarter last year, the company earned ($0.12) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Vascular Biogenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.38%), Belvedere Trading LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VBLT stock can currently be purchased for approximately $0.13.

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $9.24 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.